Recent Updates
Recently added Catalysts
PLSE Positive Sentiment

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Key Takeaway: Pulse Biosciences has formed a partnership with the Clayman Thyroid Center to utilize its innovative Nanosecond Pulsed Field Ablation technology. This collaboration will involve both commercial applications and clinical research, aiming to enhance treatment options for patients. The partnership is expected to leverage the advanced capabilities of Pulse Biosciences' nPulse Vybrance system.

Market Sentiment Analysis

POSITIVE FACTORS

  • Partnership with a reputable medical center
  • Commercial use of innovative technology
  • Potential to improve patient treatment options

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to

Frequently Asked Questions

What technology is used in the partnership?

The partnership utilizes Pulse Biosciences' Nanosecond Pulsed Field Ablation technology.

Where is the Clayman Thyroid Center located?

The Clayman Thyroid Center is located at the Hospital for Endocrine Surgery in Tampa, Florida.

What is the focus of the partnership?

The partnership focuses on commercial use and clinical collaboration for patient treatment.

Last updated: Oct 14, 2026